Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age
The 2-dose mRNA-1273 primary series elicited robust and durable (≥ 6 months) Th1-biased CD4+ T-cell responses in children aged 6 months to 11 years. CD8+ T-cell responses varied by age. Clinical Trials Registration. NCT04796896.
Authors
- James D. Campbell (ORCID: https://orcid.org/0000-0002-2931-9643)
- Bethany Girard (ORCID: https://orcid.org/0000-0001-9390-230X)
- Grant Paulsen (ORCID: https://orcid.org/0000-0002-8901-6513)
- Sabine Schnyder Ghamloush
- W. Xu
- C. Buddy Creech (ORCID: https://orcid.org/0000-0002-8276-9053)
- Christina A. Rostad (ORCID: https://orcid.org/0000-0001-8439-0592)
- Evan J. Anderson (ORCID: https://orcid.org/0000-0002-1576-4420)
- Lingyi Zheng (ORCID: https://orcid.org/0000-0002-3446-3447)
- M. Juliana McElrath (ORCID: https://orcid.org/0000-0003-2276-7117)
- Rituparna Das (ORCID: https://orcid.org/0000-0002-5166-0311)
- Stephen C. De Rosa (ORCID: https://orcid.org/0000-0003-3871-4618)
Institutions
- University of Maryland, Baltimore (US)
- Cincinnati Children's Hospital Medical Center (US)
- Emory University (US)
- Fred Hutch Cancer Center (US)
- Moderna Therapeutics (United States) (US)
- Children's Healthcare of Atlanta (US)
- University of Cincinnati (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1093/infdis/jiaf144
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19